



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Arzerra® Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis below:					
<input type="checkbox"/> Previously untreated chronic lymphocytic leukemia					
<input type="checkbox"/> Recurrent or progressive chronic lymphocytic leukemia					
<input type="checkbox"/> Refractory chronic lymphocytic leukemia					
<input type="checkbox"/> Relapsed chronic lymphocytic leukemia					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Provider's Specialty:					
Is Arzerra prescribed by or in consultation with a hematologist/oncologist? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For previously untreated chronic lymphocytic leukemia (CLL), answer the following:					
Is the patient an appropriate candidate for fludarabine-based therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Will Arzerra be used in combination with chlorambucil? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For recurrent or progressive chronic lymphocytic leukemia (CLL), answer the following:					
Is the disease recurrent or progressive? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Will Arzerra be used for the extended treatment of patients who are in complete or partial response after at least two lines of therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For refractory chronic lymphocytic leukemia (CLL), answer the following:					
Select if the disease is refractory to the following:					
<input type="checkbox"/> Campath (alemtuzumab) <input type="checkbox"/> Fludara (fludarabine)					
For relapsed chronic lymphocytic leukemia (CLL), answer the following:					
Will Arzerra be used in combination with fludarabine? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Will Arzerra be used in combination with cyclophosphamide? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Arzerra_Comm_2017Feb-W